Short Interest in Xilio Therapeutics, Inc. (NASDAQ:XLO) Increases By 317.4%

Xilio Therapeutics, Inc. (NASDAQ:XLO) was the target of a significant growth in short interest during the month of November. As of November 30th, there was short interest totalling 175,300 shares, a growth of 317.4% from the November 15th total of 42,000 shares. Based on an average daily volume of 246,400 shares, the short-interest ratio is currently 0.7 days. Approximately 0.9% of the shares of the company are sold short.

Institutional Trading of Xilio Therapeutics

A number of large investors have recently added to or reduced their stakes in the company. Geode Capital Management LLC increased its position in shares of Xilio Therapeutics by 85.0% during the 3rd quarter. Geode Capital Management LLC now owns 338,192 shares of the company’s stock valued at $266,000 after purchasing an additional 155,337 shares during the last quarter. XTX Topco Ltd bought a new position in shares of Xilio Therapeutics during the 2nd quarter valued at approximately $32,000. Finally, Renaissance Technologies LLC increased its position in shares of Xilio Therapeutics by 18.3% during the 2nd quarter. Renaissance Technologies LLC now owns 295,000 shares of the company’s stock valued at $280,000 after purchasing an additional 45,554 shares during the last quarter. Institutional investors own 54.29% of the company’s stock.

Xilio Therapeutics Price Performance

NASDAQ:XLO opened at $1.04 on Thursday. Xilio Therapeutics has a 1 year low of $0.49 and a 1 year high of $1.93. The stock’s 50 day simple moving average is $0.99 and its two-hundred day simple moving average is $0.93. The company has a market cap of $45.72 million, a price-to-earnings ratio of -0.60 and a beta of -0.29.

Analyst Upgrades and Downgrades

Separately, Raymond James lowered their price objective on Xilio Therapeutics from $6.00 to $4.00 and set an “outperform” rating on the stock in a research report on Friday, November 8th.

About Xilio Therapeutics

Xilio Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company’s checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors.